[1] |
JIA Yinyin, ZHANG Caishu, ZHOU Ying, LIU Li, GENG Ying, WEI Ningyi, NIU Sijing, CHEN Hua, XU Hui.
Evaluation methods for aerodynamic particle size distribution of fine particles in inhaled products
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 141-146.
|
[2] |
FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong.
Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184.
|
[3] |
ZHANG Jian, FANG Huihua.
Applicability of evaluation standards for use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 185-189.
|
[4] |
LI Yingfen, HAN Lei.
Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
|
[5] |
FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan.
One case of generalized myalgia caused by oxaliplatin
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210.
|
[6] |
LI Na, GUO Jun, GUO Wenjia, LYU Yinyin, LI Caihong, MU Xiangdong.
One case of delayed skin allergic reaction caused by asthma treated with omalizumab injection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 211-212.
|
[7] |
CHEN Yuyan, ZHANG Mingxia, ZHANG Tao, ZHANG Jin.
One case of interstitial pneumonia caused by serplulimab injection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 213-215.
|
[8] |
GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe.
Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5.
|
[9] |
TAI Jun, YU Miao, ZHANG Lin, LEI Yi, LIU Junting, LI Tao, HUANG Guimin, CHENG Yijing, NIE Xiaolu, WANG Qing.
Active monitoring of adverse reactions related to haemocoagulase agkistrodon for injection in children
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1011-1016.
|
[10] |
SHI Bowen, LI Lixun, XIE Yanming, WANG Zhifei, WANG Qi.
Clinical characteristics of Xiyanping injection in 3846 patients with bacterial intestinal infection in the real world
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1017-1021.
|
[11] |
YUAN Sisi, WANG Guangyan, LI Yifan, LI Ruilian, DU Boran, FENG Xin.
Safety-related risk factors in clinical management of narcotics and psychotropic substances via failure mode and effect analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1027-1030.
|
[12] |
LIU Qian, HU Jing, LI Bo, YANG Xiaojing.
Jinghuaweikang capsules combined with quadruple therapy in the treatment of Helicobacter pylori associated gastritis: a systematic evaluation and meta-analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1039-1045.
|
[13] |
HUO Yanfei, TIAN Yuejie, XU Lili, XIE Yanjun, CHANG Hong, SUN Chunxiao, LI Xia.
535 reports of new and serious adverse drug reactions caused by preparations of lappaconitine hydrobromide
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 921-926.
|
[14] |
ZHANG Xialan, YUAN Jing, WU Bin, QIN Yuanyuan.
Medications of apatinib mesylate in patients with malignant tumors
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 927-932.
|
[15] |
CHANG Yongzhuo, LI Ji, ZHANG Xiaoyan, ZHOU Chaofan.
One case of abnormal uterine bleeding caused by Baofukang suppository
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 935-938.
|